Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02221141
Recruitment Status : Unknown
Verified January 2018 by Laurence Gabriel, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur.
Recruitment status was:  Recruiting
First Posted : August 20, 2014
Last Update Posted : February 1, 2018
Sponsor:
Information provided by (Responsible Party):
Laurence Gabriel, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur

Brief Summary:

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.

Actually the early diagnosis is important because a treatment exists that can prevent future complications.


Condition or disease
Left Ventricular Hypertrophy

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Other
Study Start Date : December 2013
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation [ Time Frame: 1 day ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with left ventricular hypertrophy
Criteria

Inclusion Criteria:

  • unexplained left ventricular hypertrophy

Exclusion Criteria:

  • isolated septal hypertrophy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221141


Contacts
Layout table for location contacts
Contact: Laurence Gabriel +32 81 42 21 11 ext 3623 laurence.gabriel@uclouvain.be
Contact: Karine Jourdan +32 81 42 21 11 ext 3610 karine.jourdan@uclouvain.be

Locations
Layout table for location information
Belgium
CHU Dinant-Godinne Recruiting
Yvoir, Belgium, 5530
Principal Investigator: Laurence Gabriel         
Sponsors and Collaborators
Laurence Gabriel
Layout table for additonal information
Responsible Party: Laurence Gabriel, Dr Laurence GABRIEL, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
ClinicalTrials.gov Identifier: NCT02221141    
Other Study ID Numbers: Fabry Disease Cardioscreening
First Posted: August 20, 2014    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy, Left Ventricular
Hypertrophy
Pathological Conditions, Anatomical
Cardiomegaly
Heart Diseases
Cardiovascular Diseases